Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomised, Double-blind, Placebo-controlled Study of APD421 (Amisulpride for IV Injection) as Treatment of Established Post-operative Nausea and Vomiting, in Patients Who Have Had Prior Prophylaxis

Trial Profile

Randomised, Double-blind, Placebo-controlled Study of APD421 (Amisulpride for IV Injection) as Treatment of Established Post-operative Nausea and Vomiting, in Patients Who Have Had Prior Prophylaxis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 11 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Amisulpride (Primary)
  • Indications Postoperative nausea and vomiting
  • Focus Registrational; Therapeutic Use
  • Sponsors Acacia Pharma
  • Most Recent Events

    • 06 Dec 2023 According to Eagle Pharmaceuticals Media Release, post hoc analysis results from this trial will be presented at a the 77th PGA (PostGraduate Assembly in Anesthesiology)
    • 06 Dec 2023 Results of post hoc analysis of pivotal trials published in the Eagle Pharmaceuticals Media Release
    • 29 Sep 2021 According to a Acacia Pharma media release, based data from four positive Phase 3 studies, the company has submitted a Marketing Authorization Application (MAA) for BARHEMSYS (amisulpride injection) to prevent and treat postoperative nausea & vomiting (PONV). The MAA has been validated and is now under formal review in major European markets. The review process is expected to be completed by Q3/2022.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top